Baillie Gifford — RXRX Trade History

Quarter-by-quarter changes in the Recursion Pharmaceuticals Inc position · CUSIP 75629V104
Currently held · 5.3 YearsFirst seen: 2021 Q2
QuarterFiledActivitySharesΔ SharesΔ %Value% Port.
2026 Q22026-08-06Reduce23,487,907-187,500-0.8%$86.2M0.08%
2026 Q12026-05-08Reduce23,675,407-99,565-0.4%$72.7M0.07%
2025 Q42026-01-23Reduce23,774,972-203,723-0.8%$97.2M0.08%
2025 Q32025-10-31Reduce23,978,695-195,120-0.8%$117.0M0.09%
2025 Q22025-08-06Reduce24,173,815-219,200-0.9%$122.3M0.09%
2025 Q12025-05-07Reduce24,393,015-471,043-1.9%$129.0M0.11%
2024 Q42025-01-31Reduce24,864,058-375,812-1.5%$168.1M0.13%
2024 Q32024-11-05Reduce25,239,870-1,350,066-5.1%$166.3M0.12%
2024 Q22024-07-25Add26,589,9362,522,132+10.5%$199.4M0.15%
2024 Q12024-05-01Reduce24,067,804-111,700-0.5%$240.0M0.19%
2023 Q42024-01-26Reduce24,179,504-371,905-1.5%$238.4M0.19%
2023 Q32023-11-13Reduce24,551,409-546,221-2.2%$187.8M0.17%
2023 Q22023-07-28Reduce25,097,630-37,900-0.2%$187.5M0.16%
2023 Q12023-05-03Add25,135,530314,680+1.3%$167.7M0.15%
2022 Q42023-03-10Add24,820,8503,226,157+14.9%$191.4M0.20%
2022 Q32022-10-27Reduce21,594,693-10,992-0.1%$229.8M0.24%
2022 Q22022-08-08Reduce21,605,685-375,919-1.7%$175.9M0.18%
2022 Q12022-05-05Reduce21,981,604-141,551-0.6%$157.4M0.11%
2021 Q42022-01-20Add22,123,15561,781+0.3%$379.0M0.21%
2021 Q32021-10-19Add22,061,3743,540,374+19.1%$507.6M0.27%
2021 Q22021-08-02New18,521,00018,521,000$676.0M0.33%
2021 Q12021-05-06
2020 Q42021-02-10
2020 Q32020-11-12
2020 Q22020-08-12
2020 Q12020-05-08
2019 Q42020-02-10
2019 Q32019-11-07
2019 Q22019-08-08
2019 Q12019-05-01
2018 Q42019-02-14
2018 Q32018-11-13
2018 Q22018-07-17
2018 Q12018-05-10
2017 Q42018-02-13
2017 Q32017-10-20
2017 Q22017-08-10
2017 Q12017-05-12
2016 Q42017-02-14
2016 Q32016-11-09

Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.